SCHEMBL2256145

SCHEMBL2256145

[CH2]c1cc(OCCC)cc(OCCC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.41
PLA2G2A P14555 1/20 0.40
KMT2A Q03164 2/20 0.39
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38
MEN1 O00255 1/20 0.37
CA6 P23280 1/20 0.37
CA5A P35218 1/20 0.37
CA14 Q9ULX7 1/20 0.37
CA5B Q9Y2D0 1/20 0.37
ELANE P08246 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
PLK1 P53350 1/20 0.36
MAPT P10636 1/20 0.36
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
GPBAR1 Q8TDU6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5271649 0.88 PLA2G2A (0.47) LTA4HPLA2G2ACA12CA1CA2
SCHEMBL91974 0.87 LTA4H (0.48) LTA4HPLA2G2AKMT2ACA12CA1
SCHEMBL5266313 0.86 PLA2G2A (0.55) LTA4HPLA2G2AGPBAR1
SCHEMBL3237732 0.86 KAT6A (0.39) LTA4HKMT2ACA12CA1CA2
SCHEMBL5267874 0.85 PLA2G2A (0.58) LTA4HPLA2G2A
SCHEMBL5273089 0.85 PLA2G2A (0.58) LTA4HPLA2G2A
SCHEMBL5271277 0.85 PLA2G2A (0.58) LTA4HPLA2G2A
SCHEMBL5268054 0.85 PLA2G2A (0.58) LTA4HPLA2G2A
SCHEMBL5267532 0.85 PLA2G2A (0.58) LTA4HPLA2G2A
SCHEMBL5267390 0.85 PLA2G2A (0.58) LTA4HPLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2363390-A1 DERIVED LACTAM FROM D3 VITAMIN Teijin Pharma Limited (JP) 2011-09-07 EP disclosed
US-20110207944-A1 VITAMIN D3 LACTAM DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2011-08-25 US disclosed
CN-1294129-C Heteraryl-substituted porrole derivatives, their prep. and therapeutic use SANKYO CO (JP) 2007-01-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207944-A1 VITAMIN D3 LACTAM DERIVATIVE VDR, CYP24A1, CYP2R1 LTA4H 114/4885PLA2G2A 2148/4885KMT2A 3742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.